Bioport Posts Net Profit Turnaround in Q2 2026, Reporting 13.4% Sales Growth

Bioport (188040) announced on July 27 that it achieved a consolidated net profit turnaround in Q2 2026, with sales and operating profit growing by over two digits compared to the same period last year. According to the company's consolidated preliminary results for Q2 2026 (April 1-June 30), sales reached 218.4 billion won, a 13.4% increase from the previous year. Operating profit rose to 15.26 billion won, a 104.2% increase, while net profit turned positive at 16.83 billion won compared to a 20.1 billion won loss in the same period last year. Shareholders' equity also turned positive at 16.83 billion won. On a half-year cumulative basis, sales totaled 431.89 billion won, operating profit reached 22.91 billion won, and net profit amounted to 23.93 billion won, with sales and operating profit growing 19.6% and 215.1% year-over-year, respectively. The results are preliminary under Korean GAAP and may differ from the final figures due to lack of external audit. As of December 2025 fiscal year-end, Bioport's consolidated balance sheet showed total assets of 573 billion won, liabilities of 168 billion won, and equity of 405 billion won. Sales for the year reached 709 billion won, with an operating profit of 8 billion won and a net loss of 14 billion won. Listed on the KOSDAQ market since May 16, 2025, Bioport operates in the broader food manufacturing industry. As of July 27, 2026, its stock price was 4,935 won at 10:10 AM, up 160 won (+3.35%) from the previous day.